Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. develops clinical and preclinical biopharmaceutical programs for Wilson disease and oncology radiopharmaceuticals. News about MNPR centers on ALXN1840, also described as tiomolibdate choline, a late-stage investigational oral therapy for Wilson disease, including analyses from the Phase 3 FoCus trial, copper-balance data, neurology and hepatology conference presentations, and related peer-reviewed publications.
Company updates also cover the MNPR-101 radiopharmaceutical programs for uPAR-expressing cancers, including MNPR-101-Zr imaging activity, MNPR-101-Lu therapeutic development and IND clearance, and preclinical MNPR-101-Ac work. Recurring corporate themes include financial results, public offerings, balance-sheet updates, and commercial or executive infrastructure as the company advances its pipeline.
Monopar Therapeutics (Nasdaq: MNPR) announced the issuance of a new U.S. patent (US 10,450,340), enhancing its camsirubicin intellectual property portfolio, which may expire in 2038. This patent covers a novel family of 2-pyrrilino camsirubicin analogs designed to maintain a non-cardiotoxic profile while exhibiting broad-spectrum antitumor activity. The company is on track to initiate a Phase 2 clinical trial in early 2021, evaluating camsirubicin against doxorubicin for advanced soft tissue sarcoma. Successful development could lead to better patient outcomes by overcoming dosing limitations associated with doxorubicin.
Monopar Therapeutics (Nasdaq: MNPR) and NorthStar Medical Radioisotopes announced the selection of a uPRIT clinical candidate aimed at treating severe COVID-19. This candidate, derived from Monopar's proprietary antibody MNPR-101, targets uPAR, which is associated with pro-inflammatory immune responses. The candidate is now advancing into IND-enabling studies, with preclinical trials forthcoming. The collaboration emphasizes the urgency of developing effective treatments alongside vaccines for COVID-19 patients.
Monopar Therapeutics (MNPR) announced the initiation of its Phase 2b/3 VOICE clinical trial for Validive®, aimed at preventing severe oral mucositis (SOM) in oropharyngeal cancer patients undergoing chemoradiotherapy. The trial is actively recruiting up to 260 patients across multiple sites, following a completed Phase 2 trial that showed a 40% reduction in SOM incidence among those treated with Validive. With more than 40,000 new cases expected in the U.S. in 2021, there is a significant unmet medical need for effective SOM therapies.
Monopar Therapeutics (MNPR) announced key updates from its third quarter 2020. The Phase 2b/3 clinical trial of its lead product, Validive, targeting severe oral mucositis, is set to start before year-end. New patents have been issued for Validive, enhancing its market position. Additionally, a Phase 2 clinical trial for camsirubicin is anticipated to begin by early 2021. As of September 30, 2020, the company holds $18.0 million in cash, expected to fund operations through 2021. However, fundraising will be essential for the Phase 3 trial of Validive.
Monopar Therapeutics (Nasdaq: MNPR) has announced the issuance of new patents for Validive, its lead product candidate, which is currently in Phase 2b/3 trials. The patents extend protection to 2035, enhancing Validive’s use in preventing adverse chemotherapy effects such as gastrointestinal and respiratory disorders. With around 650,000 U.S. cancer patients undergoing chemotherapy annually, this expands Validive's application beyond oral mucositis treatment. The clinical trial for oropharyngeal cancer patients is set to commence by year-end 2020.
Monopar Therapeutics (Nasdaq: MNPR) announced that CEO Chandler D. Robinson will present a corporate update at the H.C. Wainwright 22nd Annual Global Investment Conference, focusing on healthcare and biotech. The virtual conference is scheduled for September 16, 2020, at 1:30 PM EDT. Monopar is a clinical-stage biopharmaceutical company that develops therapeutics aimed at improving the life quality of cancer patients, with a pipeline including Validive, camsirubicin, and MNPR-101.
Monopar Therapeutics (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC have partnered with The University of Texas Health Science Center at Tyler to develop urokinase plasminogen activator receptor targeted radio-immunotherapeutics (uPRITs) for severe COVID-19 treatment. UTHSCT will conduct essential preclinical and clinical studies, leveraging a $2 million NIH grant aimed at improving outcomes for hospitalized COVID-19 patients. This collaboration aims to expedite the development of uPRITs for potential first-in-human trials at UTHSCT.
Monopar Therapeutics (MNPR) announced a partnership with Aragen Bioscience to accelerate the development of urokinase plasminogen activator receptor targeted radio-immunotherapeutics (uPRITs) for treating severe COVID-19. The collaboration aims to select a lead uPRIT candidate based on the MNPR-101 antibody scaffold, advancing towards IND-enabling studies. This partnership is crucial in targeting aberrantly activated immune cells to combat severe lung injury associated with COVID-19. The initiative reflects a strong commitment to innovative therapeutic solutions amidst ongoing health challenges.
Monopar Therapeutics (Nasdaq: MNPR) announced its initiative to develop a COVID-19 test aimed at triaging patients based on their risk of severe respiratory failure. The test will utilize Monopar's antibody, ATN-658, to measure soluble urokinase plasminogen activator receptor (suPAR) levels in patient plasma. Preliminary studies suggest elevated suPAR correlates with a 17-fold increase in severe outcomes. Monopar is also collaborating with NorthStar Medical Radioisotopes on a precision therapeutic targeting aberrant immune cells in severe COVID-19 cases, potentially improving patient management.
Monopar Therapeutics (MNPR) has announced a strategic partnership with NorthStar Medical Radioisotopes and IsoTherapeutics Group to develop Radio-Immuno-Therapeutics (RITs) aimed at treating severe COVID-19. The collaboration will utilize Monopar’s experimental antibody MNPR-101, modified by IsoTherapeutics to couple with therapeutic radioisotopes from NorthStar. This initiative seeks to advance clinical trials that target immune cells implicated in severe COVID-19 outcomes. The partnership builds on previous successful collaborations and aims to improve patient outcomes significantly.